EU Funding


Together with a consortium of partners, Katairo has received funding from the European Commission.

Under the project name “Soraprazan” – which is the INN name of the active ingredient of Remofuscin – a proof-of-concept clinical trial with Remofuscin for Stargardt disease is being prepared and performed. 

The project encompasses the manufacture of the drug product, including trial site supply, regulatory affairs, the planning and execution of the clinical study managed by an industry CRO, the establishment and maintenance of a pharmacovigilance system, the communication and dissemination of results, the preparation for the exploitation of results, and the coordination of the project.

The clinical trial is scheduled to start in Q4 2018 and last through late 2021. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779317.

If you are interested in updates on this program, please subscribe to our newsletter.


The consortium includes the following partners.

Eberhard-Karls-Universität Tübingen
(coordinator, trial site)
Leiden University Medical Center
(trial site)
Ospedale San Rafaele, Milano
(trail site)
Radboud University Medical Center, Nijmegen
(trial site)
Southhampton University Hospital
(trial site)
Universitäts-Augenklinik Bonn
(trial site)
Smerud Medical Research, Oslo
(clinical research organisation)
Katairo GmbH